Pfizer and BioNTech sign new $3.2 billion COVID-19 vaccine with US govt

30 June 2022

US pharma giant Pfizer (NYSE: PFE) and German partner BioNTech (Nasdaq: BNTX) have announced a new vaccine supply agreement with the US government to support the continued fight against COVID-19.

Under the agreement, the US government will receive 105 million doses (30µg, 10µg and 3µg) of the vaccine, brand name Comirnaty, which has already generated mega sales of $36.8 billion in 2021.

This may include adult Omicron-adapted COVID-19 vaccines, subject to authorization from the US Food and Drug Administration (FDA). The doses are planned to be delivered as soon as late summer 2022 and continue into the fourth quarter of this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK